Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07233148 · ClinicalTrials.gov registry record
Healing ALS Registry Observational Study (HAROS)
A clinical trial of Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS), sponsored by Healing Advocates Registry and Ministry.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT07233148 is a study of Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS) that is actively recruiting participants, run by Healing Advocates Registry and Ministry. The registered enrollment target is 1,000 participants, above the 202-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (395% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07233148, a study of Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS), is actively recruiting participants, sponsored by Healing Advocates Registry and Ministry.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, observational, online study of people diagnosed with ALS, MND or PLS referred to as HAROS (Healing ALS Registry Observational Study). Participants will enter information into an online ALS registry once per month, including their ALSFRS-R data, certain other symptoms, dietary intake, supplements, medications and other therapies, both conventional and integrative. Participants will also enter the hours spent on optional self-study and free online education. The investigators will assess the effectiveness of various therapies and education by measuring physical outcomes.
Conditions Studied
Interventions
- OTHER Education about treatment options
- DIETARY_SUPPLEMENT Dietary Supplements: Vitamins, Minerals, Herbs, etc.
- BEHAVIORAL Meditation, Prayer, Talk Therapy, Affirmations, Journaling, etc.
- OTHER Diet, various diets will be observed
- OTHER Exercise, physical therapy, occupational therapy, speech therapy, sauna, EMS, massage and other therapies
Study Locations (1)
Utah
- Virtual - Park City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-01-26 |
| Est. Completion | 2036-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07233148
The ClinicalTrials.gov registry entry for NCT07233148 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (395% higher). The listed sponsor is Healing Advocates Registry and Ministry, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 5 interventions - of which Education about treatment options is the first listed.
NCT07233148 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT07233148 about?
NCT07233148 is a clinical study titled "Healing ALS Registry Observational Study (HAROS)". This is a prospective, observational, online study of people diagnosed with ALS, MND or PLS referred to as HAROS (Healing ALS Registry Observational Study). Participants will enter information into an online ALS registry once per month, including their ALSFRS-R data, certain other symptoms, dietary ...
What is the current status of trial NCT07233148?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2026-01-26. Estimated completion is 2036-03-31.
What conditions does trial NCT07233148 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease (MND).
What interventions are being tested in trial NCT07233148?
The interventions under investigation include: Education about treatment options (OTHER), Dietary Supplements: Vitamins, Minerals, Herbs, etc. (DIETARY_SUPPLEMENT), Meditation, Prayer, Talk Therapy, Affirmations, Journaling, etc. (BEHAVIORAL), Diet, various diets will be observed (OTHER), Exercise, physical therapy, occupational therapy, speech therapy, sauna, EMS, massage and other therapies (OTHER).
Who is sponsoring clinical trial NCT07233148?
This trial is sponsored by Healing Advocates Registry and Ministry, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07233148 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
RECRUITING · Phase 1
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RECRUITING · Phase 2
-
Retinal Imaging in Neurodegenerative Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.